English
|
Spanish
Login
Register
For the latest
e
cancer COVID-19 resources, click on this link
Home
News
Journal
Video
e
learning
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
Conferences
Sign up for latest coverage
Submit your event
Conferences
e
cancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Past
Upcoming
Category
All
Disease Areas
Patient Care
Policy
Prevention & screening
Treatments
Sub-category
All
Region
All
Asia
Middle East and North Africa
Europe
North America
Central America and the Caribbean
South America
Africa
Australia and Oceania
Country
All
Year
All
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Keyword
ASH 2020
3 - 8 Dec 2020
Online, Virtual, United States of America
Videos
News
The Burkitt lymphoma international prognostic index
Prof Adam Olszewski - Brown University, Providence, USA
24 Dec 2020
Results of venetoclax and azacitidine combination in chemotherapy ineligible unt...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
22 Dec 2020
Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
22 Dec 2020
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL ...
Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA
16 Dec 2020
Researchers trace the origin of blood cancer to early childhood, decades before ...
Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK
16 Dec 2020
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma
Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eri...
15 Dec 2020
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patien...
Dr Francesca Gay - University of Torino, Torino, Italy
14 Dec 2020
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosp...
Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy
11 Dec 2020
FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multi...
Dr Elena Zamagni - University of Bologna, Bologna, Italy
10 Dec 2020
Clinical activity and safety of cevostamab in relapsed/refractory multiple myelo...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
10 Dec 2020
ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia
Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany
10 Dec 2020
ASCENT: A phase II trial of induction, consolidation and maintenance in subjects...
Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA
9 Dec 2020
Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukae...
Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Nether...
9 Dec 2020
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab
Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands
9 Dec 2020
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CL...
Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA
9 Dec 2020
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
9 Dec 2020
ASH 2020: Targeted therapies in r/r multiple myeloma
Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar
8 Dec 2020
Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment
Prof Monica Bocchia - University of Siena, Siena, Italy
8 Dec 2020
Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve se...
Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA
8 Dec 2020
Treating acute leukaemias of ambiguous lineage
Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Ho...
8 Dec 2020
Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China...
Dr Shaji Kumar and Dr Wenming Chen
8 Dec 2020
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T31...
Dr Jorge Cortes - Augusta University, Augusta, USA
8 Dec 2020
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combina...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
8 Dec 2020
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin l...
Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia
8 Dec 2020
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
8 Dec 2020
Off-the-shelf multi-virus specific T cells following haematopoietic stem cell tr...
Dr Bilal Omer - Baylor College of Medicine, Houston, USA
8 Dec 2020
Blinatumomab and oral TKIs for the treatment of Ph ALL
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
8 Dec 2020
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
8 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
8 Dec 2020
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-ye...
Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany
7 Dec 2020
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patien...
Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain
7 Dec 2020
FORTE trial: Impact of minimal residual disease on multiple myeloma patients
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
7 Dec 2020
Evaluation of MRD negativity in patients with relapsed or refractory multiple my...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
7 Dec 2020
ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma
Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA
7 Dec 2020
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma
Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA
7 Dec 2020
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in ne...
Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA
7 Dec 2020
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelph...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
7 Dec 2020
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
7 Dec 2020
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Trea...
Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands
7 Dec 2020
Predictive factors for overall survival in chronic myeloid leukaemia patients: a...
Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy
6 Dec 2020
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potent...
Prof David Teachey - The University of Pennsylvania, Rutledge, USA
6 Dec 2020
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukae...
Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA
5 Dec 2020
More from
e
cancer